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Abstract
This paper presents an up-to-date review of the evidence indicating that atypical neurotransmitters such as nitric oxide (NO) 
and endocannabinoids (eCBs) play an important role in the regulation of aversive responses in the periaqueductal gray (PAG). 
Among the results supporting this role, several studies have shown that inhibitors of neuronal NO synthase or cannabinoid 
type 1 (CB1) receptor agonists cause clear anxiolytic responses when injected into this region. The nitrergic and eCB systems 
can regulate the activity of classical neurotransmitters such as glutamate and γ-aminobutyric acid (GABA) that control PAG 
activity. We propose that they exert a ‘fine-tuning’ regulatory control of defensive responses in this area. This control, however, 
is probably complex, which may explain the usually bell-shaped dose-response curves observed with drugs that act on NO- or 
CB1-mediated neurotransmission. Even if the mechanisms responsible for this complex interaction are still poorly understood, 
they are beginning to be recognized. For example, activation of transient receptor potential vanilloid type-1 channel (TRPV1) 
receptors by anandamide seems to counteract the anxiolytic effects induced by CB1 receptor activation caused by this com-
pound. Further studies, however, are needed to identify other mechanisms responsible for this fine-tuning effect. 
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The periaqueductal gray matter (PAG) is a midbrain 
structure that surrounds the Sylvius aqueduct and has been 
implicated in the modulation of cardiovascular and motor 
control, nociceptive information and defensive responses 
(1,2). In laboratory animals, stimulation of the dorsal parts 
of the PAG leads to full-blown escape responses accom-
panied by sympathetic arousal (3). These escape reactions 
are attenuated by serotonin reuptake inhibitors (SSRIs) 
(4), first choice drugs in the treatment of several anxiety 
disorders. 
The involvement of the PAG in defensive behaviors 
has also been supported by clinical studies. Electrical 
stimulation of the deep layers of the superior colliculus and 
periaqueductal gray matter in neurosurgery patients causes 
intense fear and a feeling of imminent death accompanied 
by autonomic changes such as increased blood pressure 
and heart rate (5). These responses are similar to those 
described for animals facing an imminent, proximal threat 
such as a predator. Accordingly, recent neuroimaging stud-
ies in healthy volunteers have shown that the dorsal part 
of the PAG is activated during the presentation of proximal 
threats (6). 
On the basis of the similarity between these reactions 
and panic attacks, as well as on the pharmacological re-
sponse to SSRIs, stimulation of the PAG has been proposed 
as a model of panic attack (4). Several lines of evidence 
support this proposal, indicating that the PAG, particularly 
its dorsal part, is a crucial structure in the defensive sys-
tem (7). 
Classical neurotransmitters, the PAG and 
defensive behaviors
Several neurotransmitters are present in the PAG, inter-
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acting in a complex way to control defensive responses in 
this region (8-11). The main excitatory input to the PAG is 
glutamatergic, and glutamate receptors are widely distrib-
uted throughout this region (12). There is a vast literature 
demonstrating that intra-PAG administration of glutamate 
or an N-methyl-D-aspartate (NMDA) glutamate receptor 
agonist promotes defensive responses (13,14). On the 
other hand, direct injections of NMDA and non-NMDA 
receptor antagonists into the dorsal PAG (dPAG) induce 
anxiolytic-like effects in animal models such as the elevated 
plus maze (EPM) and the Vogel conflict test (VCT) (15-17). 
Metabotropic glutamate receptors (mGluR) in the dPAG 
could also play a role in anxiety modulation. For example, 
intra-dPAG administration of a group I and II mGluR agonist 
induced flight reactions, an effect attenuated by pretreatment 
with mGluR1 and mGluR5 antagonists (18).
Besides glutamatergic neurotransmission, drugs that 
mimic or enhance the effects of the inhibitory neurotransmit-
ter γ-amino-butyric-acid (GABA), such as the GABA-A ago-
nist muscimol or benzodiazepine receptor agonists, as well 
as those that facilitate serotoninergic transmission through 
the activation of 5-hydroxytryptamine-1A (5-HT1A) or 5-HT2 
receptors, attenuate the aversive consequences of dPAG 
electrical stimulation and produce anxiolytic-like effects in 
animal models of anxiety (19-21). Moreover, whereas the 
intra-dPAG injections of serotonergic antagonists have no 
effect on defensive responses, the microinjection of GABA-A 
antagonists elicits, by itself, explosive escape reactions (21) 
similar to those induced by local electrical stimulation. These 
data suggest that GABAergic mechanisms tonically inhibit 
the PAG network that controls defensive behaviors, whereas 
serotonin exerts a phasic inhibition of this network. 
Several neuropeptides have also been implicated 
in the generation and elaboration of defense responses 
mediated by the dPAG. For example, direct injections of 
corticotrophin-releasing hormone (CRH), substance P or 
cholecystokinin (CCK) into the dPAG produce anxiogenic-
like effects (22-24). 
Atypical neurotransmitters
Several key discoveries made during the 80s and 
the early 90s have established the concept of atypical 
neurotransmitters. These substances, contrary to classi-
cal neurotransmitters, are produced ‘on demand’ in and 
released from the postsynaptic neuronal membrane. Being 
highly liposoluble, they can act presynaptically to modify 
neurotransmitter release (25,26). The two main atypical 
neurotransmitters are nitric oxide (NO) and the endocan-
nabinoids (eCBs). NO is a short-lived gas produced from 
the amino acid l-arginine by a family of enzymes called NO 
synthases (NOS) (25). The neuronal NOS (nNOS) isoform 
is constitutive in the central nervous system (CNS) and 
located in specific brain regions. It is related to glutamate 
NMDA receptors and activated postsynaptically by calcium 
influx through these receptors (26). 
The eCBs were isolated following the identification of a 
cannabinoid receptor now named CB1 and the subsequent 
search for endogenous ligands. The first recognized can-
nabinoid receptor agonist was arachidonoyl-ethanolamide, 
or anandamide (AEA) (27). Since then other endogenous 
CB1 agonists have been isolated. They include 2-arachi-
donoyl glycerol (2-AG), N-arachidonoyl dopamine, nola-
dine, and virodhamine (27), all of them arachidonic acid 
derivatives (27). 
Several lines of evidence indicate that these atypical 
neurotransmitters can modulate defensive behavior. For 
example, systemic administration of drugs that act on NO- 
or eCB-mediated neurotransmission modify anxiety-like 
behavior in different animal models (28,29). Moreover, both 
the nNOS enzyme and CB1 receptors have been located 
in key brain areas related to defensive behaviors, including 
the PAG (28-30). 
NO, PAG and defensive behavior
In the PAG, nNOS-containing neurons are located spe-
cifically in the dorsolateral column (30). Local injections of 
NOS inhibitors or NO scavengers into this region induce 
anxiolytic-like effects in distinct animal models of anxiety 
that include the EPM, VCT and predator exposure (29,31-
33). In contrast, NO donors injected into the dorsolateral 
PAG (dlPAG) induced flight responses (34,35) (Table 1). 
Additionally, studies using cFos immunohistochemistry 
as a tool to reveal neuronal activation show that different 
aversive conditions such as exposure to an EPM, restraint 
stress or a predator or ethanol withdrawal activates NOS-
positive neurons in this region (36-39). 
In the CNS, the effects of NO are exerted mainly 
through the activation of the soluble guanylate cyclase 
(sGC) enzyme leading to increased levels of cGMP (25). 
Accordingly, defensive behaviors induced by NO donors in 
the dlPAG depend on activation of local sGC, since these 
effects are attenuated by previous local injection of ODQ, 
a GC inhibitor (34). Moreover, a cGMP analogue (8-bromo-
cGMP) injected into the dlPAG also induced fight/flight 
behavior similar to NO donors, with GC inhibitors inducing 
anxiolytic-like effects in animals exposed to the EPM and 
VCT (28,33). In agreement with these results, Chiavegatto 
et al. (40) showed that exposure to a live cat increases the 
production of citrulline (an indirect index of NOS activity) and 
cGMP in the dlPAG in rats. Taken together, these results 
indicate that the effects of NO on the dlPAG are probably 
mediated by the sGC/cGMP pathway. 
Since NO is a diffusible gas, it can modulate the effects 
of several neurotransmitters such as glutamate, GABA, 
5-HT, CCK, and cannabinoids (25) that have been related 
to the control of defensive behaviors in the PAG. As men-
tioned before, in the CNS there is reciprocal regulation 
between glutamate and NO, since activation of nNOS is 
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dependent on Ca2+ influx induced by activation of NMDA 
receptors (25). Electrophysiological data showed that 
excitatory postsynaptic potentials induced by NO in dPAG 
slices are reduced by antagonists of ionotropic glutamate 
receptors (41). Reinforcing the possibility that NO effects 
in the PAG depend on facilitation of glutamate-mediated 
neurotransmission, we showed that local pretreatment with 
AP7, an NMDA receptor antagonist, blocked the aversive-
like reaction induced by linsidomine chlorhydrate (SIN-1) 
(42) and reduced the activation of NOS neurons induced by 
predator exposure (36). More recently, we determined if the 
defensive reactions induced by NMDA in the dlPAG would 
depend of endogenous NO. Our experiments, performed 
with rats, showed that the escape responses induced by 
NMDA in the dlPAG are independent of endogenous NO 
(31). However, in mice these responses were prevented 
by a selective nNOS inhibitor (43,44). This difference may 
be related to the different species or the doses of NMDA 
employed.
The aversive reactions of NO donors in the dlPAG could 
also be modulated by 5-HT neurons, which are known to 
inhibit panic-like responses (21). Local injections of 5-HT2A 
receptor agonists reduced the escape reaction induced by 
SIN-1, a nitric oxide donor (45). Moreover, intradorsal raphe 
nucleus administration of the 5-HT1A receptor agonist, 
8-OH-DPAT, which inhibits the activity of 5-HT neurons, 
favored the expression of escape induced by SIN-1 in the 
dPAG (46). The effects of 5-HT on flight responses induced 
by SIN-1 may involve indirect GABAergic facilitation, since 
5-HT2 receptors are co-expressed in GABAergic neurons 
(8). In agreement with these results, defensive-like re-
sponses induced by intra-dlPAG administration of SIN-1 
were attenuated by midazolam, a benzodiazepine receptor 
agonist (47).
It is also possible that the effects of NO on the PAG 
involve a direct interference with GABA-mediated neu-
rotransmission, since GABA-expressing neurons in the 
dlPAG are co-expressed with nNOS-positive neurons (8). 
Moreover, electrophysiological studies performed in dlPAG 
slices showed that NO can potentiate the synaptic release 
of GABA (48). 
eCB, PAG and defensive behavior
In the PAG, eCBs, similar to NO, modulate the release of 
several neurotransmitters that regulate defensive behaviors 
(29,53). CB1 receptors and the fatty acid amide hydrolase 
(FAAH) enzyme, responsible for AEA degradation, are 
complementarily expressed along the PAG (54). Moreover, 
systemic or intracerebroventricular administration of CB1 
agonists increases cFos expression in the PAG (55) and 
AEA and 2-AG levels increase in this region after exposure 
to aversive footshock stress (56). Taken together, these 
lines of evidence indicate that eCBs could also be related 
to defensive reactions in this region. Accordingly, local ad-
ministration of the synthetic cannabinoid HU210 attenuated 
defensive behaviors induced by either intra-dPAG injection 
of excitatory amino acid or by ultrasound exposure (57,58) 
and intra-PAG administration of drugs that increase eCB-
signaling potentiates stress-induced analgesia (56). 
Table 1. Effects of nitric oxide-related drugs on defensive behavior when injected into the intradorsal periaqueductal gray 
region.
Drug (dose) Possible mechanism Species Animal model Main effect References
Carboxy-PTIO (0.3-3 nmol) NO scavenger Rat VCT, EPM Anxiolytic 21,28*,33
OA No effect
DEA/NO (150-600 nmol) NO donor Rat OA Pro-aversive 35
L-NOARG (10-100 nmol) NOS inhibitor Rat EPM Anxiolytic 32*
L-NAME (100-200 nmol) NOS inhibitor Rat EPM, T-maze Anxiolytic 31,32*,49
OA No effect
Methylene blue (10-100 nmol) sGC and NOS inhibitor Rat EPM Anxiolytic 50*
NOC-9 (75-150 nmol) NO donor Rat OA Pro-aversive 34
NPA (0.08-100 nmol) Selective nNOS inhibitor Rat, Mice VCT, CET, RET Anxiolytic 33,36,51
SIN-1 (150-300 nmol) NO donor Rat OA Pro-aversive 28,34,35,45
ODQ (0.3-3 nmol) sGC inhibitor Rat EPM Anxiolytic 28*,31,52
OA No effect
7NI (40 nmol) Preferential nNOS inhibitor Rat EPM No effect 52
Drugs: Carboxy-PTIO = 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide potassium salt; DEA/NO = dieth-
ylamine NONOate; L-NOARG = N(G)-nitro-L-arginine; L-NAME = N(G)-nitro-L-arginine methyl ester hydrochloride; NOC-9 = 
6-(2-hydroxy-1-methyl-2-nitrosohydrazino)-N-methyl-1-hexanamine; NPA = n-propyl-L-arginine; SIN-1 = 3-(4-morpholinyl)syd-
nonimine; ODQ = 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; 7-NI = 7-nitro-indazol. Mechanisms: NO = nitric oxide; NOS = 
NO synthase; sGC = soluble guanylyl cyclase; nNOS = neuronal NOS. Models: VCT = Vogel conflict test; EPM = elevated plus-
maze; OA = open arena; CET = cat exposure test; RET = rat exposure test. *Indicates a bell-shaped dose-response curve.
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In an attempt to better understand the involvement of 
eCBs in defensive behaviors controlled by the dlPAG, our 
group showed that local injection of AEA induces anxiolytic-
like effect in animals exposed to the EPM through activation 
of CB1 receptors (59). Anxiolytic-like effects were mimicked 
by arachidonoylchloroethanolamide (ACEA), a selec-
tive CB1 agonist, and potentiated by the inhibitor of AEA 
transport, AM404. However, as frequently observed after 
systemic injections, AEA and ACEA produced a bell-shaped 
dose-response curve, with the higher doses being ineffective 
(59). Moreover, intra-dlPAG-administered AM404 by itself 
failed to cause any effect in the EPM (59) (Table 2).
These anxiolytic-like effects of AEA in the dlPAG were 
subsequently confirmed in two other animal models of 
anxiety, the VCT and contextual fear conditioning test 
(CFC) (60,61). Different from the EPM, however, in these 
studies drugs that inhibit AEA uptake/metabolism induced 
anxiolytic-like effects. One possible interpretation for this 
discrepancy is that the eCB system in the PAG is more 
intensely recruited under higher stress situations, such 
as those that involve aversive electrical shocks like the 
VCT and CFC. Accordingly, in CB1 knockout mice the 
light intensity in the behavioral test room was shown to 
be a crucial factor to determine the levels of anxiety of 
the animals (62). 
The role of the eCB system in defensive behaviors 
mediated by the PAG was more recently investigated in 
two panic models, predator (cat) exposure and electrical 
stimulation of the dPAG. As observed previously in anxiety 
models, intra-dlPAG injection of AEA induced antiaversive 
effects in both models (63, and Lisboa SF and Guimaraes 
FS, unpublished results). Taken together, these results 
strongly suggest that eCBs play an important modulatory 
role in the defensive behaviors mediated by the PAG. 
This role could involve regulation of glutamate-mediated 
neurotransmission, since cannabinoid agonists have been 
shown to inhibit glutamatergic synaptic transmission in this 
region (64). Interaction with mGluR could also be important. 
In the PAG activation of mGluR, subtype 5 (mGluR5) induces 
the release of eCBs, which, in turn, activate presynaptic 
cannabinoid CB1 and cause analgesia (65). 
eCBS can also change GABAergic neurotransmission 
in the PAG. Local blockade of GABA receptors attenuates 
cannabinoid-induced sympathoexcitation and pressor re-
sponses, suggesting that eCBs could facilitate sympathetic 
activation by disruption of GABAergic neurotransmission in 
the PAG (66). It remains to be confirmed if interference with 
GABA-related mechanisms is involved in the bell-shaped 
dose-response curves observed when CB1 agonists are 
injected into the PAG (59). 
Table 2. Effects of cannabinoid- and vanilloid-related drugs on defensive behavior when injected into the intradorsal periaque-
ductal gray region.
Drug (dose) Possible mechanism Species Animal model Main effect References
ACEA (0.01-5 pmol) CB1/TRPV1 agonist Rat EPM Anxiolytic 59*,63
EsES Panicolytic
AEA (0.5-50 pmol) CB1/TRPV1 agonist Rat EPM, VCT Anxiolytic 59*,60,61
CFC ↓CER
AM251 (10-100 pmol) CB1 antagonist Rat EPM, VCT No effect 59,60,67
AM404 (50 pmol) AEA uptake/metabolism inhibitor Rat VCT Anxiolytic 60,61
CFC ↓CER
Capsazepine (0.1-60 nmol) TRPV1 antagonist Rat EPM, VCT Anxiolytic 63,64
EsES Panicolytic
Capsaicin (0.01-1 nmol) TRPV1 agonist Rat EsES Anxiolytic 69
CBD (10-60 nmol) 5-HT1A agonist Rat EPM, ETM Anxiolytic 67* 
EsES Panicolytic
HU210 (0.25-12.9 nmol) CB1 agonist Rat EsCS, EsUs Antiaversive 57,58
SB366791 (10 nmol) TRPV1 selective antagonist Rat EsES Panicolytic 63
URB597 (0.01 nmol) AEA metabolism inhibitor Rat VCT Anxiolytic 60
WIN55,212-2 (3-30 pmol) CB1/TRPV1 agonist Rat EPM Anxiolytic 68
Drugs: ACEA = arachidonoylchloroethanolamide; AEA = anandamide; CBD = cannabidiol. Mechanisms: CB1 = cannabinoid 
receptor type 1; TRPV1 = transient receptor potential vanilloid type-1 channel; 5-HT1A = 5-hydroxytryptamine-1A. Models: EPM 
= elevated plus-maze; EsES = escape induced by dPAG electrical stimulation; VCT = Vogel conflict test; CFC = contextual fear 
conditioning; ETM = elevated T-maze; EsCS = escape induced by dPAG chemical stimulation; EsUs: escape induced by ultra-
sound. Effects: CER = conditioned emotional response. *Indicates a bell-shaped dose-response curve.
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Endovanilloids, PAG and defensive 
behaviors
Initially identified in the periphery as a receptor for the 
pungent ingredient of red-hot chili peppers, capsaicin, 
the transient receptor potential vanilloid type-1 channel 
(TRPV1) is also expressed in the CNS, where it can el-
evate calcium levels and potentiate synaptic transmission 
(29). Anandamide, together with N-arachidonoyldopamine, 
N-oleoylethanolamine and hydroperoxyeicosatetraenoic 
acids, has been proposed as one of its putative endogenous 
agonists, called endovanilloids (29). 
The dual action of AEA as an agonist of CB1 and TRPV1 
receptors has been related to the dual effects of this and 
other cannabinoids in several areas, including the PAG 
(63,70). TRPV1 receptors are expressed in this and other 
regions related to the control of defensive responses (71). 
In the PAG, electrophysiological studies have shown that 
capsaicin, a TRPV1 receptor agonist, facilitates the release 
of glutamate by a presynaptic mechanism, indicating that 
these receptors are functional in this region (72). Several 
other studies, however, have also indicated a postsynaptic 
localization of TRPV1 receptors in forebrain limbic regions 
(73).
Although there are few studies in the literature in-
vestigating the effects of TRPV1-selective agonists on 
PAG-mediated defensive behaviors, direct microinjection 
of antagonists into this region suggests that the endova-
nilloid system plays an important role in modulating these 
behaviors (see Table 2). For example, intra-dPAG injection 
of TRPV1 antagonists such as capsazepine and SB366791 
caused anxiolytic- and panicolytic-like effects, respectively, 
in different animal models (63,64). 
These results suggest that TRPV1 receptors are tonically 
activated by endovanilloids such as anandamide, facilitating 
vanilloid-mediated defensive responses. However, another 
possibility to explain these results is an interaction between 
the endovanilloid and endocannabinoid systems, in a way 
that the presence of TRPV1 antagonists allows for a se-
lective anandamide effect, redirecting its action entirely to 
CB1 receptors (63). 
Supporting this proposal, activation of TRPV1 recep-
tors has been related to the bell-shaped dose-response 
curves usually produced by cannabinoid compounds. It was 
demonstrated, for example, that whereas the anxiolytic-
like effect of intra-dPAG administration of the anandamide 
analogue ACEA is mediated by CB1 receptors, the loss of 
this response seen with higher ACEA doses is reversed 
when the animals are pretreated with TRPV1 antagonists 
(63). Similar effects were demonstrated for the synthetic 
cannabinoid WIN55,212-2 (that can also activate CB1 and 
TRPV1 receptors) and the non-psychotomimetic phytocan-
nabinoid cannabidiol (67,68). Although the latter compound 
has a complex pharmacology, at high doses it can activate 
TRPV1 receptors (67). 
Contrasting with these results, dlPAG-injection of the 
TRPV1 agonist capsaicin induced anxiolytic-like effects in 
rats submitted to the EPM and VCT (64). Studies in pe-
ripheral tissues, however, have shown that this drug can 
induce a rapid desensitization of TRPV1 receptors (74). At 
present it is still unclear, however, if a similar mechanism 
occurs in the PAG. 
Possible interactions between atypical 
neurotransmitters in the control of 
defensive behaviors
Several in vitro studies (75-78) have suggested a func-
tional interaction between the cannabinoid and nitrergic 
systems in the CNS and peripheral tissues. This possible 
interaction involves different components of these two 
systems. For example, studies with endothelial cells and 
synaptosomes derived from rat brain, as well as an ex-vivo 
model of blood-brain barrier, suggest that NO can control 
the activity of the proposed AEA transporter (77). 
Stimulation of CB1 receptors by different cannabinoid 
agonists enhances nNOS activity, increasing the produc-
tion of cGMP (75,76). This effect is involved in some in 
vivo cannabinoid effects such as AEA-induced inhibition of 
depolarization-evoked dopamine release in leech ganglia 
and stimulation of neuropeptide release from the mammalian 
median eminence (77,79). Also, the usual development of 
tolerance to the acute hypothermic and cataleptic effects 
observed with cannabinoid agonists such as WIN55,212-
2 is prevented by repeated administration of L-NAME, a 
non-specific NOS inhibitor (80). Corroborating this finding, 
some acute effects of tetrahydrocannabinol (THC), including 
hypolocomotion and hypothermia, are decreased in nNOS 
knockout mice. This same study demonstrated that several 
nNOS-positive neurons co-express CB1 receptors in the 
caudate-putamen and hypothalamus, two brain regions re-
lated to motor and temperature control, respectively (81).
 Although these studies indicate that CB1 activation can 
induce NO production, opposite results have been reported. 
For example, the potent CB1 agonist CP-55,940 was able 
to decrease NO release in microglial cells stimulated with 
an endotoxin (82) and L-NAME increased the central hy-
pothermic effect of the CB1 agonist WIN55,212-2 in rats 
(83). In addition, in cultures of rat cerebellar granule cells, 
depolarization-induced Ca2+ influx and subsequent NOS 
activation were reduced by WIN55,212-2 through inhibition 
of voltage-gated Ca2+ channels (84). Moreover, animals 
that lack the CB1 gene present an increase in NOS activ-
ity in the cerebral cortex, suggesting that CB1 is required 
to inhibit this activity (85). These results suggest that the 
interaction between CB1 and NOS activation is complex, 
with the former, under certain conditions, counteracting 
some effects of NO. 
In the dlPAG, as mentioned earlier, NOS inhibitors, NO 
scavengers and sGC inhibitors cause anxiolytic-like effects 
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in animal models (28), whereas NO donors induce flight 
reactions (28,34). The latter responses are prevented by 
local pretreatment with NMDA and non-NMDA glutamate 
receptor antagonists, suggesting, as shown elsewhere (25), 
that the effects of NO donors in the dlPAG are mediated by 
facilitation of glutamate release. As seen, CB1 receptors 
are also present in the PAG (54) where they can decrease 
glutamate release (64). This mechanism could explain the 
similar anxiolytic effects found after intra-dlPAG adminis-
tration of CB1 receptor agonists (59-61) and glutamate 
ionotropic receptor antagonists (15,16). 
Since NO and eCBs can regulate, usually in opposite 
directions, the release of neurotransmitters such as gluta-
mate and GABA, and based on the several lines of evidence 
discussed above indicating that these two systems regulate 
defensive responses, we determined if they interact in the 
dlPAG to modulate these responses. In agreement with 
this proposal, low doses of AEA or an FAAH inhibitor ad-
ministered into the dlPAG attenuated the flight responses 
induced by an NO donor, suggesting that activation of CB1 
receptors could decrease NO-induced glutamate release. 
Also, the CB1 receptor antagonist AM251 not only prevented 
the effects of AEA but also increased the effect of NO (86). 
The latter effect could involve TRPV1 receptors since, as 
discussed before, in the PAG CB1 and TRPV1 receptors can 
be simultaneously activated at a given synapse to modulate 
defensive-like responses (63). Activation of TRPV1 has 
also been shown to promote NO formation in endothelial 
cells and in the placenta (87,88) and capsazepine was 
able to decrease the defensive reactions induced by an 
NO donor effect in the dlPAG (Aguiar DC and Guimaraes 
FS, unpublished results).
In the PAG activation, presynaptic TRPV1 receptor has 
been shown to increase glutamate release (72). However, 
it is possible that postsynaptic receptors are also involved. 
This has been recently observed by Zschenderlein et al. (89) 
in another brain region related to defensive responses, the 
lateral amygdala. They showed that, after high frequency 
stimulation, capsaicin activates postsynaptic TRPV1 recep-
tors. This could activate nNOS and increase NO production 
by facilitating Ca2+ entry, resulting in presynaptic glutamate 
release and enhancement of long-term potentiation (LTP). At 
low frequency stimulation, on the other hand, postsynaptic 
TRPV1 activation could induce AEA synthesis, which in turn 
activates presynaptic CB1 receptors, reducing glutamate 
release and inhibiting LTP. It remains to be determined if 
similar mechanisms occur in the PAG. 
Conclusions
The studies reviewed above clearly indicate that, in 
addition to classical neurotransmitters such as glutamate, 
GABA, serotonin, and neuropeptides, atypical transmitter 
molecules can also regulate defensive responses in the 
dlPAG.
Since these transmitters, which include NO, endocan-
nabinoids and endovanilloids, exert most of their effects 
by modulating the release and/or effects of these classical 
neurotransmitters, they also play a ‘fine-tuning’ regulatory 
role in these responses. Several pharmacological results 
obtained in this region, together with a few electrophysi-
ological and microdialysis data, indicate that this ‘fine-tuning’ 
role involves glutamate-mediated neurotransmission. At 
low doses AEA could activate CB1 receptors and attenuate 
defensive behaviors by decreasing glutamate release, while 
at higher doses it becomes ineffective or even increases 
these responses by also activating TRPV1 receptors and 
facilitating glutamate release. NO, on the other hand, may 
also participate in this fine-tuning role by increasing glu-
tamate release. In addition, NO formation would also be 
modulated in a dual way by AEA through activation of CB1 
and TRPV1 receptors. 
Although these results have mostly focused on gluta-
mate, based on what has been described in other brain 
regions, it is most reasonable that other neurotransmitters 
such as GABA and serotonin are also involved in the ef-
fects of these atypical transmitters. This issue needs to be 
further investigated in future studies.
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